» Articles » PMID: 25465164

Long-term Outcome of Biopsy-proven Minimal Change Nephropathy in Chinese Adults

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2014 Dec 4
PMID 25465164
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Minimal change nephropathy is a common cause of primary nephrotic syndrome in adults. However, there are few studies of its clinical course, response to treatment, and long-term outcome.

Study Design: Retrospective cohort study.

Setting & Participants: 340 consecutive adult patients with nephrotic syndrome and biopsy-proven minimal change nephropathy treated in a university hospital from 1984 until 2004.

Factors: Treatment response groups: primary steroid resistance, frequent relapse (≥4 relapses within 1 year), infrequent relapse (≥1 relapse but not frequent relapse), and no relapse (reference group); disease pattern.

Outcome: Medical problems after diagnosis; patient survival; renal survival.

Results: Median time to remission was 10 (IQR, 8-12) weeks; 179 (52.6%) had no relapse, 42 (12.4%) had infrequent relapses, 86 (25.3%) were frequent relapsers or steroid dependent, and 33 (9.7%) had primary steroid resistance. After a median follow-up of 174.7 (IQR, 119.7-235.0) months, 32 patients developed end-stage renal disease and 62 died (25 after progression to end-stage renal disease). Cox regression analysis showed that age and treatment response groups were the independent predictors of patient survival. Compared to the no-relapse group, the infrequent-relapse group had significantly better patient survival (adjusted HR, 0.19; 95% CI, 0.08-0.44; P<0.001), whereas the primary-steroid-resistance group had significantly worse patient survival (adjusted HR, 5.87; 95% CI, 1.83-18.85; P<0.001). Renal survival was excellent except in the primary-steroid-resistance group.

Limitations: Retrospective study.

Conclusions: A substantial proportion of adult patients with minimal change nephropathy continue to have disease flares more than 10 years after the initial presentation, and medical problems after diagnosis are common.

Citing Articles

Adult minimal change disease: Clinicopathologic characteristics, treatment response and outcome at a single center in Pakistan.

Shakeel S, Rashid R, Jafry N, Mubarak M World J Nephrol. 2024; 13(4):99643.

PMID: 39723355 PMC: 11572659. DOI: 10.5527/wjn.v13.i4.99643.


Activation of the inflammasome and pyroptosis cascade in podocytes of patients with minimal change disease.

Kajio Y, Suzuki T, Kobayashi K, Kanazawa N, Iyoda M, Honda H Clin Kidney J. 2024; 17(8):sfae216.

PMID: 39114498 PMC: 11304592. DOI: 10.1093/ckj/sfae216.


Key pathological features characterize minimal change disease-like IgA nephropathy.

Wang T, Chang F, Yang A, Ka S, Chen A, Hsieh J PLoS One. 2023; 18(7):e0288384.

PMID: 37471324 PMC: 10358932. DOI: 10.1371/journal.pone.0288384.


Steroid Minimization in Adults with Minimal Change Disease.

Koirala A, Jefferson J Glomerular Dis. 2023; 1(4):237-249.

PMID: 36751385 PMC: 9677715. DOI: 10.1159/000517626.


Nicorandil protects podocytes via modulation of antioxidative capacity in acute puromycin aminonucleoside-induced nephrosis in rats.

Yamanaka M, Tamura Y, Kuribayashi-Okuma E, Uchida S, Shibata S Am J Physiol Renal Physiol. 2022; 324(2):F168-F178.

PMID: 36454699 PMC: 9844977. DOI: 10.1152/ajprenal.00144.2022.